Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GlaxoSmithKline
National Cancer Institute (NCI)
Artios Pharma Ltd
Incyte Corporation
Centre Oscar Lambret
Merck Sharp & Dohme LLC
Eli Lilly and Company
City of Hope Medical Center
National Cancer Institute (NCI)
Seagen Inc.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Acrivon Therapeutics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
OHSU Knight Cancer Institute
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Incyte Corporation
ImmunityBio, Inc.
Sutro Biopharma, Inc.
Mural Oncology, Inc
Merck Sharp & Dohme LLC
Jiangsu HengRui Medicine Co., Ltd.
Toray Industries, Inc
Yonsei University
Universitaire Ziekenhuizen KU Leuven
The University of Hong Kong
NGM Biopharmaceuticals, Inc
National Institute of Cancerología
National Institute of Cancerología
National Cancer Institute (NCI)
AGO Research GmbH